Sugi Predict

Sugi Predict / Compounds / SCHEMBL570540

SCHEMBL570540

SCHEMBL570540

O=C(CCCCCCC(=O)Oc1ccc([N+](=O)[O-])cc1)Oc1ccc([N+](=O)[O-])cc1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BCL9 O00512 1/20 0.73
▸ CTNNB1 P35222 1/20 0.73
▸ TDP1 Q9NUW8 1/20 0.55
▸ GAA P10253 1/20 0.54
▸ MGLL Q99685 2/20 0.54
▸ PTPN7 P35236 1/20 0.54
▸ PTPN12 Q05209 1/20 0.54
▸ PTPN22 Q9Y2R2 1/20 0.54
▸ KMT2A Q03164 4/20 0.53
▸ SMN1; SMN2 Q16637 2/20 0.51
▸ MAPT P10636 2/20 0.51
▸ NPC1 O15118 1/20 0.51
▸ RAB9A P51151 1/20 0.51
▸ EGFR P00533 2/20 0.50
▸ ERBB2 P04626 2/20 0.50
▸ PKM P14618 1/20 0.50
▸ ALDH1A1 P00352 2/20 0.47
▸ CA1 P00915 1/20 0.46
▸ CA2 P00918 1/20 0.46
▸ CES2 O00748 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL530771 1.00 BCL9 (0.73) BCL9CTNNB1TDP1GAAMGLL
SCHEMBL531155 1.00 BCL9 (0.73) BCL9CTNNB1TDP1GAAMGLL
SCHEMBL7079988 1.00 BCL9 (0.73) BCL9CTNNB1TDP1GAAMGLL
SCHEMBL531007 0.98 BCL9 (0.76) BCL9CTNNB1TDP1GAAMGLL
SCHEMBL3919600 0.95 BCL9 (0.76) BCL9CTNNB1TDP1GAAMGLL
SCHEMBL12189868 0.94 BCL9 (0.66) BCL9CTNNB1TDP1GAAMGLL
SCHEMBL16915260 0.94 BCL9 (0.66) BCL9CTNNB1TDP1GAAMGLL
SCHEMBL531330 0.94 BCL9 (0.66) BCL9CTNNB1TDP1GAAMGLL
SCHEMBL29164403 0.94 BCL9 (0.66) BCL9CTNNB1TDP1GAAMGLL
SCHEMBL31758269 0.94 BCL9 (0.66) BCL9CTNNB1TDP1GAAMGLL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114456373-B Leucine-based polyester amide nano drug delivery system and preparation method and application thereof 中山大学 2023-05-26 — — CN disclosed
CN-114456373-A Nano drug delivery system of polyesteramide based on leucine and preparation method and application thereof 中山大学 2022-05-10 — — CN disclosed
CN-110804177-B Polyesteramide nano drug delivery system based on lysine and preparation method and application thereof 中山大学 2021-02-26 — — CN disclosed
CN-110804177-A Polyesteramide nano drug delivery system based on lysine and preparation method and application thereof 中山大学 2020-02-18 — — CN disclosed
WO-2016040814-A2 DISULFIDE POLYMERS AND METHODS OF USE THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) 2016-03-17 — — WO disclosed
US-8637492-B2 Molecular transporter compositions comprising dendrimeric oligoguanidine with a tri-functional core that facilitates delivery into cells in vivo GENE TOOLS, LLC (US) 2014-01-28 — — US disclosed
US-8637492-B2 Molecular transporter compositions comprising dendrimeric oligoguanidine with a tri-functional core that facilitates delivery into cells in vivo GENE TOOLS, LLC (US) 2014-01-28 — — US disclosed
US-20120035358-A1 Molecular transporter compositions comprising dendrimeric oligoguanidine with a tri-functional core that facilitates delivery into cells in vivo GENE TOOLS, LLC 2012-02-09 — — US disclosed
US-20120035358-A1 Molecular transporter compositions comprising dendrimeric oligoguanidine with a tri-functional core that facilitates delivery into cells in vivo GENE TOOLS, LLC 2012-02-09 — — US disclosed
US-7935816-B2 Molecular transporter compositions comprising dendrimeric oligoguanidine with a triazine core that facilitate delivery into cells in vivo GENE TOOLS, LLC (US) 2011-05-03 — — US disclosed
US-20090171075-A1 Molecular transporter compositions comprising dendrimeric oligoguanidine with a triazine core that facilitate delivery into cells in vivo GENE TOOLS, LLC 2009-07-02 — — US disclosed
US-20090111775-A1 Molecular transporter compositions comprising dendrimeric oligoguanidine with a tri-functional core that facilitates delivery into cells in vivo GENE TOOLS, LLC 2009-04-30 — — US disclosed
WO-2009055027-A2 MOLECULAR TRANSPORTER COMPOSITIONS COMPRISING DENDRIMERIC OLIGOGUANIDINE WITH A TRI-FUNCTIONAL CORE THAT FACILITATE DELIVERY INTO CELLS IN VIVO LI YONG-FU (US) 2009-04-30 — — WO disclosed
EP-0562624-A2 Stabilization of functional proteins Modrovich, Ivan E. (US) 1993-09-29 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090111775-A1 Molecular transporter compositions comprising dendrimeric oligoguanidine with a tri-functional core that facilitates delivery into cells in vivo SLC29A2, SLC29A1, SLC2A9 BCL9 1802/4885CTNNB1 2943/4885TDP1 1341/4885
US-20090171075-A1 Molecular transporter compositions comprising dendrimeric oligoguanidine with a triazine core that facilitate delivery into cells in vivo SLC18A1, SLC75A1, SLC2A1 BCL9 2079/4885CTNNB1 2573/4885TDP1 1765/4885
US-20120035358-A1 Molecular transporter compositions comprising dendrimeric oligoguanidine with a tri-functional core that facilitates delivery into cells in vivo SLC29A2, SLC29A1, SLC2A9 BCL9 1802/4885CTNNB1 2943/4885TDP1 1341/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.